

## Supplementary Online Content

Tedesco D, Gori D, Desai KR, et al. Drug-free interventions to reduce pain or opioid consumption after total knee arthroplasty: a systematic review and meta-analysis. *JAMA Surg*. Published online August 16, 2017. doi:10.1001/jamasurg.2017.2872

eTable 1. Risk of Bias Summary From Randomized Clinical Trials for Non-Pharmacological Postoperative Pain Management After Total Knee Arthroplasty

eTable 2. GRADE of Evidence Assessment for Non-Pharmacological Postoperative Pain Management After Total Knee Arthroplasty

eTable 3. Summary of Key Review Findings for Non-Pharmacological Postoperative Pain Management After Total Knee Arthroplasty

eFigure 1. PRISMA Flowchart Depicting the Search Strategy

eFigure 2. Pain Relief: Cryotherapy

eFigure 3. Pain Relief: Continuous Passive Motion (CPM)

eFigure 4. Pain Relief: Continuous Passive Motion (CPM)

eFigure 5. Pain Relief: Preoperative Exercise

eFigure 6. NSAID Consumption: Cryotherapy

eFigure 7. Opioid Consumption: Acupuncture

eFigure 8. Opioid Consumption: Continuous Passive Motion (CPM)

eFigure 9. Acupuncture

eFigure 10. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 11. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 12. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 13. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 14. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 15. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 16. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 17. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 18. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

© 2017 American Medical Association. All rights reserved.

eFigure 19. Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation

eFigure 20. Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)

eFigure 21. Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)

eFigure 22. Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)

eFigure 23. Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)

eFigure 24. Funnel Plot of Comparison for CPM Trials Measured in Terms of Reported Points in the VAS Scale at 1 Week

eFigure 25. Funnel Plot of Comparison for CPM Trials Measured in Terms of Opioid Consumption (mg/kg/48 Hours of Morphine Equivalent)

eFigure 26. Funnel Plot of Comparison for Cryotherapy Trials Measured in Terms of Reported Points in the VAS Scale

eFigure 27. Funnel Plot of Comparison for Cryotherapy Trials Measured in Terms of Opioid Consumption (mg/kg/48 Hours of Morphine Equivalent)

eFigure 28. Funnel Plot of Comparison for Electrotherapy Trials Measured in Terms of Reported Points in the VAS Scale at 1 Week

eFigure 29. Funnel Plot of Comparison for Acupuncture Trials Measured in Terms of Reported Points in the VAS Scale at 1 Week

eFigure 30. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 31. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 32. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 33. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 34. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 35. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 36. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 37. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 38. Subgroup Sensitivity Analysis Comparing Studies by Type of Control

eFigure 39. Subgroup Sensitivity Analysis Comparing Studies by Time (Studies Divided If Published Prior or Comprising Year 2000 or From 2001 Onwards)

eFigure 40. Subgroup Sensitivity Analysis Comparing Studies by Time (Studies Divided If Published Prior or Comprising Year 2000 or From 2001 Onwards)

eFigure 41. Results of the Meta-Regression for the Distribution of Age in the Groups (Treatment vs Control)

eFigure 42. Results of the Meta-Regression for the Distribution of Sex in the Groups (Treatment vs Control)

© 2017 American Medical Association. All rights reserved.

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2017 American Medical Association. All rights reserved.

**eTable 1.** Risk of Bias Summary from Randomized Controlled Trials for Non-pharmacological Postoperative Pain Management after Total Knee Arthroplasty.

<b>Study</b>	<b>Random sequence generation</b>	<b>Allocation concealment</b>	<b>Incomplete outcome data</b>	<b>Selective outcome reporting</b>	<b>Other sources of bias</b>	<b>Blinding</b>
<i>Adravanti et al. (2013)</i>	Low	High	Unclear	High	Low	High
<i>Albrecht et al. (2008)</i>	Unclear	Unclear	Low	Unclear	Unclear	High
<i>Beauprè et al. (2001)</i>	Unclear	Unclear	Low	Unclear	Low	High
<i>Bennett et al. (2005)</i>	Low	Low	Low	High	Low	High
<i>Borckardt et al. (2013)</i>	Low	Low	Low	Unclear	Low	High
<i>Bruun-Olsen et al. (2009)</i>	High	Low	Low	Low	Unclear	High
<i>Calatayud et al. (2016)</i>	Low	Low	Low	Low	Unclear	High
<i>Chen et al. (2013)</i>	High	High	Unclear	Unclear	Low	High
<i>Chen et al. (2015)</i>	Unclear	Unclear	Low	Unclear	Unclear	High
<i>Colwell et al. (1992)</i>	Unclear	Unclear	Low	High	Low	High
<i>Denis et al. (2006)</i>	Low	Low	Low	Low	Low	High
<i>Gibbons et al. (2001)</i>	Unclear	Unclear	Low	High	Low	High

© 2017 American Medical Association. All rights reserved.

<i>Gstoettner et al. (2011)</i>	Low	Low	Unclear	Low	Low	High
<i>Harms et al. (1991)</i>	Unclear	Unclear	Unclear	High	Low	High
<i>Ivey et al. (1994)</i>	Low	Low	Unclear	Unclear	Unclear	Low
<i>Kim et al. (2009)</i>	Low	Unclear	Unclear	Low	Unclear	High
<i>Kullenberg et al. (2006)</i>	Unclear	Unclear	Low	High	Low	High
<i>Lenssen et al. (2003)</i>	Low	Low	Low	Low	Low	High
<i>Lenssen et al. (2008)</i>	Low	Low	Low	High	Low	High
<i>Levy et al. (1993)</i>	Unclear	Unclear	Unclear	High	Low	Unclear
<i>MacDonald et al. (2000)</i>	Low	Low	Unclear	High	Low	High
<i>Maniar et al. (2012)</i>	High	Low	Unclear	Low	High	High
<i>May et al. (1999)</i>	Unclear	Low	Low	High	Low	High
<i>McKay et al. (2012)</i>	Unclear	High	Low	Unclear	Low	High
<i>McInnes et al. (1992)</i>	High	Low	Low	Low	Unclear	High
<i>Mikashima et al. (2012)</i>	Low	Low	Low	Unclear	Unclear	Unclear
<i>Montgomery et al. (1996)</i>	High	Unclear	Low	Unclear	Low	High
<i>Moretti et al. (2012)</i>	Low	Low	High	High	Unclear	High

© 2017 American Medical Association. All rights reserved.

<i>Morsi E. (2002)</i>	High	High	Low	High	Low	High
<i>Pope et al. (1997)</i>	Unclear	Unclear	Low	Unclear	Unclear	High
<i>Radkowski et al. (2007)</i>	Low	Unclear	Low	High	Low	Low
<i>Sahin et al. (2006)</i>	High	Unclear	Low	Low	Unclear	High
<i>Smith et al. (2002)</i>	High	Unclear	Low	Unclear	Unclear	High
<i>Su et al. (2012)</i>	Unclear	Unclear	Low	Unclear	Low	High
<i>Thienpont et al. (2014)</i>	Low	Low	Low	Low	Unclear	Unclear
<i>Tsang et al. (2007)</i>	Low	Low	Low	High	Unclear	Unclear
<i>Tzeng et al. (2015)</i>	Unclear	Low	Unclear	Unclear	Low	High
<i>Walker et al. (1991)</i>	Unclear	Unclear	Low	Unclear	Low	Unclear
<i>Webb et al. (1998)</i>	Unclear	Unclear	Low	Unclear	Low	Unclear

© 2017 American Medical Association. All rights reserved.

**eTable 2.** GRADE of Evidence Assessment for Non-pharmacological Postoperative Pain Management after Total Knee Arthroplasty.

Study Outcome	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	GRADE
<b>Pain relief – VAS</b>						
CPM	Very Serious	Not Serious	Not Serious	Serious	Not Serious	⊕ Very Low
Cryotherapy	Very Serious	Serious	Not Serious	Not Serious	Serious	⊕ Very Low
Electrotherapy	Very Serious	Serious	Not Serious	Not Serious	Serious	⊕ Very Low
Acupuncture	Serious	Serious	Not Serious	Not Serious	Not Serious	⊕⊕ Low
<b>Pain relief – WOMAC</b>						
CPM	Very Serious	Not Serious	Not Serious	Not Serious	Not Serious	⊕⊕ Low
Preoperative exercise	Serious	Serious	Not Serious	Not Serious	Not Serious	⊕⊕ Low
<b>Opioid consumption</b>						
CPM	Serious	Serious	Not Serious	Serious	Not Serious	⊕ Very Low
Cryotherapy	Serious	Serious	Not Serious	Not Serious	Serious	⊕ Very Low
Electrotherapy	Serious	Not Serious	Not Serious	Not Serious	Not Serious	⊕⊕⊕ Moderate

© 2017 American Medical Association. All rights reserved.

Acupuncture	Serious	Serious	Not Serious	Not Serious	Not Serious	⊕⊕ Low
<b>NSAID consumption</b>						
Cryotherapy	Very Serious	Serious	Not Serious	Serious	Not Serious	⊕ Very Low
<b>Time to first PCA</b>						
Acupuncture	Serious	Not Serious	Not Serious	Not Serious	Not Serious	⊕⊕⊕ Moderate

© 2017 American Medical Association. All rights reserved.



**eTable 3.** Summary of Key Review Findings for Non-pharmacological Postoperative Pain Management after Total Knee Arthroplasty.

Study	Duration of intervention	Outcome measure timepoints	Primary outcome measure	Secondary outcome measure	Main findings/Conclusion	Conflict of interest/funding disclosure
<b>Continuous passive motion (CPM)</b>						
<i>Beauprè et al. (2001)</i>	3 days postoperatively (PO)	3 and 6 months PO	Knee extension and flexion	WOMAC (Pain, Stiffness, Function), SF36	Self-reported pain, function, or overall quality of life was not different at either of the postoperative measurement times.	Study funded by a grant from the Health Services Research and Innovation Fund, Canada.
<i>Bennett et al. (2005)</i>	6 days PO	3 months, 1 year PO	Range of Motion (ROM)	Length of stay (LOS), Pain, Wound healing, Perceived Health Status Measure SF-12	Statistically significant differences in mean pain scores between groups. The differences are not clinically significant ( $\leq 1$ point on a 10-point scale).	Funds received in partial or total support of the research material described in this article from the Alfred Grant, Australia.

<i>Brunn-Olsen et al. (2009)</i>	6 to 12–14 weeks PO	14 weeks, 9 months PO	Pain (VAS scale)	ROM	CPM was not found to have an additional short-time effect compared with physiotherapy. After three months pain relief was obtained.	A grant for the study was received from the Norwegian Foundation of Postgraduate Physiotherapists. Conflict of interest not stated.
<i>Chen et al. (2013)</i>	3 days PO	2 weeks, 6 weeks, 3month, 6 month PO	ROM	Pain	No significant difference	Project funded by the National Health Research Institute, Taiwan.
<i>Colwell et al. (1992)</i>	3 days PO	1, 2 and 3 days PO	ROM	Analgesia use	CPM reduces opioid consumption and LOS.	Not stated.
<i>Denis et al. (2006)</i>	9 days PO	Discharge	ROM (flexion, extension, Timed up and go test - TUG)	WOMAC (Pain, Stiffness, Function)	The results do not support the addition of CPM applications to conventional physical therapy. CPM did not show to further reduce knee impairments or disability or the length of the hospital stay.	Not stated.
<i>Harms et al. (1991)</i>	6hr/day for 1 week PO	Discharge	Pain (VAS scale)	ROM, LOS	No significant differences found in VAS scores	Not stated.

© 2017 American Medical Association. All rights reserved.

<i>Kim et al. (2009)</i>	20 minutes/day, from day 2 to day 14 PO	Flexion contracture and maximum flexion: day 7 after TKA, day 14. 6 weeks, 3 months and 6 months. Level of pain during ROM exercise: day 7 and day 14.	Flexion contracture, maximum flexion	AKS knee score, AKS function score, WOMAC pain, WOMAC stiffness, WOMAC function	Regular passive ROM exercise does not offer additional clinical benefits to the patients after TKA	Not stated.
<i>Lenssen et al. (2003)</i>	4 days PO	4days	Pain (VAS scale)	ROM	No significant differences found in VAS scores	Not stated.
<i>Lenssen et al. (2008)</i>	4 hours/day for 4 days PO	17 day, 6 weeks, 3 months	Function and pain (WOMAC scale), ROM	Medication Use, Satisfaction	No significant differences found in WOMAC scores	The authors declare that they have no competing interests.
<i>MacDonald et al. (2000)</i>	6 weeks PO	6, 12, 26 weeks, and 1 year PO	Function (KSS scale)	ROM, Pain	No significant differences found in VAS scores	Not stated
<i>Maniar et al. (2012)</i>	Day 1 and 3 PO	3, 5, 14±2, 42±5, 90±10	Pain-VAS, ROM, TUG, swelling and wound healing	WOMAC, SF-12	No significant differences found in VAS scores	The Conflict of Interest disclosure related to this article available at doi:10.1016/j.arth.2011.04.009.
<i>May et al. (1999)</i>	1 week PO	1 month	ROM, VAS,	LOS	No differences at	Not stated.

© 2017 American Medical Association. All rights reserved.

			KSS		VAS outcome	
<i>McInnes et al. (1992)</i>	Starting within 24 hours from surgery	7 days, 6 weeks	Cost	Pain (VAS scale), swelling, ROM	No significant differences found in VAS scores	Study supported by National Institutes of Health.
<i>Montgomery et al. (1996)</i>	3 hours 3 times daily, 7 days a week	1, 3, 5 days PO	Pain (VAS scale)	Mid-patellar effusion, Knee flexion, ROM	Postoperative pain levels and LOS similar in the two groups.	Not stated.
<i>Pope et al. (1997)</i>	1 week PO	Up to 1 year PO	ROM	Blood loss, analgesia use	Clinical disadvantages in the short term in CPM groups with no worthwhile improvement in the range of movement or function.	No benefits in any form received from a commercial party.
<i>Sahin et al. (2006)</i>	1 week PO	2 weeks, 6 weeks, 6 months PO	ROM, Pain (VAS scale)	Swelling, KSS score	No significant differences found in VAS scores in CPM groups	Not stated.
<i>Walker et al. (1991)</i>	From day 3 PO until discharge	1 month, 12 months.	Manipulation, adverse events	ROM, pain (VAS scale), LOS	CPM showed a significant reduction in analgesia consumption	Supported by a grant from the National Institutes of Health, General Clinical Research Center Branch. Division of Research Resources.
<b>Preoperative exercise</b>						

© 2017 American Medical Association. All rights reserved.

<i>Calatayud et al. (2016)</i>	3 days/week for 8 weeks before surgery	8 weeks before surgery (T1), after 8 weeks of training (T2), 1 month after TKA (T3) and finally 3 months after TKA (T4)	WOMAC functional and pain scale	SF-36 scale, pain VAS scale, TUG	The present study supports the use of preoperative training in end-stage OA patients to improve early postoperative outcomes.	The authors did not receive financial support for this study, and there are no known conflicts of interest associated with this publication that could have influenced its outcome.
<i>Gstoettner et al. (2011)</i>	1 day/week for 6 weeks before surgery.	6 weeks pre-operatively; 6 weeks PO	Balance, gait speed, and function	WOMAC pain and stiffness subscales, KSS scale	There was a significant improvement in KSS, WOMAC pain and stiffness within both groups after TKA. No difference in clinical outcome was observed between the two groups.	Not stated.
<i>McKay et al. (2012)</i>	3 days/week for 6 weeks before surgery	Baseline testing 6 weeks ( $\pm 3$ days) before surgery. Before TKA, at 6 and 12 weeks after TKA,	Isometric quadriceps strength.	Mobility, pain, self-reported function, health-related quality of life, and arthritis self-	Reduction of pain within the groups, but there is not a direct comparison between them. Perceived functional ability shows an inverse relationship to pain,	Not stated.

© 2017 American Medical Association. All rights reserved.

		participants completed the questionnaire battery and physical testing.		efficacy.	but no information on significance.	
<b>Cryotherapy</b>						
<i>Albrecht et al. (2008)</i>	2 days PO	1 week PO	VAS Scale	Blood loss, ROM, Adverse effects	Significant reduction in VAS for CT group	Not stated.
<i>Gibbons et al. (2001)</i>	6 hours/day throughout the hospital stay	Blood loss: during the procedure. Amount of morphine received: over the 48 h The amount of oral analgesia: up to the 10-day stage. Pain scores recorded on alternate days after a period of physiotherapy at the end	Blood loss	ROM, pain scores, analgesia, LOS, complications	No difference was found between the 2 groups except for less blood loss in the surgical drains in the cold compression group.	Not stated.

© 2017 American Medical Association. All rights reserved.

		of the afternoon. The range of movement: 10 days after TKA.				
<i>Ivey et al. (1994)</i>	72 hours PO	Number of attempts: every hour PO Amount of morphine: daily	Pain	Number of Patient-controlled analgesia (PCA) attempts	Different temperature did not show any significant differences in pain improvement after surgery, and in the amount of injected morphine.	Not stated.
<i>Kullenberg et al. (2006)</i>	3 days PO	Up to 3 weeks PO	ROM	Pain, LOS, Hemoglobin loss	Cold compression therapy improves control of pain and might lead to improvement in ROM and reduce the length of hospital stay.	No benefits or funds were received in support of the study.
<i>Levy et al. (1993)</i>	4 days PO	Up to 2 weeks PO	Blood loss	Pain, ROM	Significant lower blood loss and morphine consumption in the intervention group; Significant	Not stated.

© 2017 American Medical Association. All rights reserved.

					improvement in ROM at 7 and 14 days from surgery.	
<i>Morsi E. (2002)</i>	2 weeks PO	Up to 6 weeks after discharge	Analgesic consumption	Pain score, ROM	Continuous-flow cold therapy is advantageous after TKA. It showed to provide better results in all the areas compared.	Not stated.
<i>Radkowski et al. (2007)</i>	Postsurgical period until discharge	2 weeks PO	Adverse events	Pain, Analgesia, Blood loss, ROM	Postoperative narcotic consumption, postoperative drainage, self-reported knee function, and range of motion were not affected by the different cryotherapy temperatures.	Not stated.
<i>Smith et al. (2002)</i>	Treatment 1 for 24 hours after surgery; treatment 2 for 6 hours; and then cryo-pad	Day 1-3 PO	Function, swelling	Pain, Analgesia	Not significant differences in pain improvement	Not stated.

© 2017 American Medical Association. All rights reserved.



<i>Su et al. (2012)</i>	Inpatient stay: 2 hours on plus 1 hour off for a minimum of 4 cycles per day. After discharge: 1 hour on plus 30 minutes off for a minimum of 4 cycles per day.	Pre-operative, 2 weeks, 6 weeks PO	ROM and function	Pain (VAS scale) and morphine consumption	No improvement in ROM and pain perception. Significant decrease in pain medication consumption and higher satisfaction.	Not stated.
<i>Thienpont et al. (2014)</i>	Postsurgical period	Day 2, 6 weeks PO	Pain (VAS scale), and analgesics consumption.	ROM, swelling, and blood loss.	Advanced cryotherapy with a continuous cooling for a prolonged period did not provide an earlier recovery.	The authors report no conflict of interest. All conflict of interest forms are on file with the publication.
<i>Webb et al. (1998)</i>	48 hours PO	Pre-operative, 5 days, 6 weeks, 3 months PO	Blood loss	Pain scores, pain medication consumption, and ROM	Cryo/cuff showed improvement in postoperative blood loss and pain but did not influence swelling and return to motion	Not stated

<i>Walker et al. (1991)</i>	From day 3 PO until discharge	Discharge, 3 months	Manipulation, adverse events	ROM, pain (VAS scale), LOS	Cryotherapy showed a significant reduction in analgesia request.	Supported by a grant from the National Institutes of Health, General Clinical Research Center Branch. Division of Research Resources.
<b>Electrotherapy</b>						
<i>Adravanti et al. (2013)</i>	2 months PO	1 month, 2 months, 6 months, 3 years PO	Pain (VAS scale)	KSS function score, SF36 score, Knee swelling	PEMFs showed significant differences in pain improvement and in functional scores in all timepoints.	One of the authors is employee of the device manufacturer.
<i>Borckardt et al. (2013)</i>	80 minutes/day in postoperative period	48 hours PO	Opioid Consumption	Pain (BPI and VAS scales)	TENS may be able to reduce post-TKA opioid requirements.	Not stated.
<i>Moretti et al. (2012)</i>	Treatment began within seven days from TKA, and consisted of 4-hour sessions/day for 60 days PO	Pre-operatively, and at 1, 2, 6, 12 months PO	Pain (VAS scale)	Knee Society Score; SF-36; Joint swelling score; Functional score	PEMFs showed significant differences in pain improvement and in functional scores in all timepoints.	Two of the authors are employees of the device manufacturer.
<i>Walker et al. (1991)</i>	From day 3 PO until discharge	3 day PO, discharge	Manipulation, adverse events	ROM, pain (VAS scale), LOS	TENS did not show a significant difference in analgesia consumption.	Supported by a grant from the National Institutes of Health, General Clinical Research Center Branch. Division of Research

© 2017 American Medical Association. All rights reserved.

---

Resources.

---

**Acupuncture**

<i>Chen et al. (2015)</i>	20 minutes/day in the postoperative period	2, 4, 8, 12, 24, 36, 48 hours PO	Opioid consumption	Time to the first PCA request; pain intensity	Acupuncture showed significant pain improvement and opioid consumption.	The authors declare that they have no competing interests.
<i>Mikashima et al. (2012)</i>	3 times/week from day 7 until day 21 PO	6, 14, 21 days PO	VAS pain score	Swelling; time to achieve preoperative ROM	Acupuncture showed significant improvement in pain, reduction of swelling around the knee and early recovery of ROM.	Not stated.
<i>Tsang et al. (2007)</i>	Postsurgical period	4-8, 11-15 days PO	Pain at rest and at maximum after exercise (VAS scale).	ROM, TUG.	Acupuncture did not show significant improvement in pain, reduction of swelling around the knee and early recovery of ROM.	The authors declare that they have no competing interests.


© 2017 American Medical Association. All rights reserved.

---


<i>Tzeng et al. (2015)</i>	48 hours PO	48 hours PO	Time for first PCA request	N/A	Acupuncture showed significant longer time to the first demand for Patient-controlled Analgesia.	Supported by China Medical University under the Aim for Top University Plan of the Ministry of Education, Taiwan and by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence. The authors declare that they have no competing interests.
----------------------------	-------------	-------------	----------------------------	-----	--	--

---


**eFigure 1.** PRISMA Flowchart Depicting the Search Strategy.




**eFigure 2. Pain relief: Cryotherapy**



**eFigure 3. Pain relief: Continuous Passive Motion (CPM)**




**eFigure 4. Pain relief: Continuous Passive Motion (CPM)**







**eFigure 5. Pain relief: Preoperative Exercise**




**eFigure 6. NSAID Consumption: Cryotherapy**




**eFigure 7. Opioid consumption: Acupuncture**




**eFigure 8. Opioid consumption: Continuous Passive Motion (CPM)**




**eFigure 9. Acupuncture**




**eFigure 10:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation



**eFigure 11: Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation**




**eFigure 12:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation







**eFigure 13:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation




**eFigure 14:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation




**eFigure 15:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation




**eFigure 16:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation




**eFigure 17: Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation**




**eFigure 18:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation



**eFigure 19:** Subgroup Sensitivity Analysis Comparing Studies Based on Allocation Concealment and Random Sequence Generation




**eFigure 20: Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)**







**eFigure 21: Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)**




**eFigure 22:** Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)




**eFigure 23:** Subgroup Sensitivity Analysis Comparing Studies Based on How Pain Outcome Was Considered (Either Primary or Secondary)




**eFigure 24:** Funnel Plot of Comparison for CPM Trials Measured in Terms of Reported Points in the VAS Scale at 1 Week




**eFigure 25:** Funnel Plot of Comparison for CPM Trials Measured in Terms of Opioid Consumption (mg/kg/48 Hours of Morphine Equivalent)




**eFigure 26:** Funnel Plot of Comparison for Cryotherapy Trials Measured in Terms of Reported Points in the VAS Scale



**eFigure 27:** Funnel Plot of Comparison for Cryotherapy Trials Measured in Terms of Opioid Consumption (mg/kg/48 Hours of Morphine Equivalent)




**eFigure 28:** Funnel Plot of Comparison for Electrotherapy Trials Measured in Terms of Reported Points in the VAS Scale at 1 Week







**eFigure 29:** Funnel Plot of Comparison For Acupuncture Trials Measured in Terms of Reported Points in the VAS Scale at 1 Week




**eFigure 30: Subgroup Sensitivity Analysis Comparing Studies by Type of Control.**




**eFigure 31: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**




**eFigure 32: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**




**eFigure 33: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**




**eFigure 34: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**



**eFigure 35: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**




**eFigure 36: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**







**eFigure 37: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**




**eFigure 38: Subgroup Sensitivity Analysis Comparing Studies by Type of Control**



**eFigure 39: Subgroup Sensitivity Analysis Comparing Studies by Time (Studies Divided If Published Prior or Comprising Year 2000 or From 2001 Onwards)**



**eFigure 40:** Subgroup Sensitivity Analysis Comparing Studies by Time (Studies Divided If Published Prior or Comprising Year 2000 or From 2001 Onwards)



**eFigure 41: Results of the Meta-regression for the Distribution of Age in the Groups (Treatment vs Control)**

. metareg AGE Group, wsse ( SD)

```

Meta-regression                                Number of obs =      28
REML estimate of between-study variance        tau2              =    .6622
% residual variation due to heterogeneity      I-squared_res    =    0.00%
Proportion of between-study variance explained Adj R-squared    =   53.35%
With Knapp-Hartung modification
  
```

AGE	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
Group	-1.365645	1.703033	-0.80	0.430	-4.86628	2.134991
_cons	68.7297	1.19114	57.70	0.000	66.28128	71.17813

**eFigure 42: Results of the Meta-regression for the Distribution of Sex in the Groups (Treatment vs Control)**

. metareg SEX Group1, wsse ( SD1)

```

Meta-regression                                Number of obs =      57
REML estimate of between-study variance        tau2              =   213.6
% residual variation due to heterogeneity      I-squared_res    =   95.96%
Proportion of between-study variance explained Adj R-squared    =   -1.26%
With Knapp-Hartung modification
  
```

SEX	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
Group1	2.310076	4.002792	0.58	0.566	-5.711698	10.33185
_cons	68.4375	3.045668	22.47	0.000	62.33385	74.54115